ClinicalTrials.gg
CompletedNCT03891875ReCLAIM-2Updated Jul 12, 2024Results posted

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

A Phase 2 interventional study of Subcutaneous elamipretide through the elamipretide delivery system and Subcutaneos placebo through the elamipretide delivery system in Age-related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 37 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
122nd of 491
176 · median 55
Started
2019
with 31 others
Phase 2
138 of 645
14 open now
Registered
413th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 122nd largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2019, is one of 138 in phase 2, and was the 413th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.

Read the detailed description

This was a randomized, double-masked, placebo controlled study using three periods to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy. The total duration of subject participation was up to 54 weeks, including a Screening Period (≤2 weeks), Treatment Period (48 weeks), and Follow-up (4 weeks). 176 eligible subjects were randomized in a 2:1 ratio (elamipretide:placebo) to receive 40 mg elamipretide or placebo. The study drug (i.e., elamipretide or placebo) was administered once daily via SC injection using the elamipretide delivery system during the 48 week Treatment Period. After completion of the 48-week Treatment Period subjects continued to be monitored for safety during the 4-week Follow-up Period and an end of study (EOS) Follow-up Visit was conducted at Week 52.

03

Conditions studied

  • Age-related Macular Degeneration

Keywords

  • AMD
  • Macular degeneration
  • non-central geographic atrophy
  • MTP-131
  • elamipretide
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 55 years of age with at least 1 eye with AMD with non-central GA as determined by FAF.

Ocular conditions-study eye

  • GA in the study eye at the Screening Visit may be multi-focal, but the cumulative GA lesion and size must:

    1. be ≥ 0.05 mm2 and ≤ 10.16 mm2 and
    2. reside completely within the FAF 30 or 35 degree image.
    3. must be at least 150 μm from foveal center with preserved outer retinal structural details
  • No evidence of CNV by history, OCT or FA in the study eye.
  • BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) score of ≥ 55 letters (Snellen equivalent ≥ 20/70) in the study eye at the Screening Visit and Baseline Visit.
  • LL BCVA by ETDRS score of ≥ 10 letters in the study eye at the Screening Visit and Baseline Visit.
  • LL VA deficit (defined as difference the between BCVA and LL BCVA) of > 5 letters in the study eye at Screening and Baseline Visits.
  • The fellow eye may have any of the following: no AMD, AMD without GA, AMD with GA, CNV AMD, or central GA. Ongoing treatment with anti-angiogenic therapies in the fellow eye is allowable.
  • Sufficiently clear ocular media, adequate pupillary dilation, fixation to permit quality fundus imaging, and ability to cooperate sufficiently for adequate ophthalmic visual function testing and anatomic assessment in the study eye.

Systemic and general criteria

Exclusion criteria

Exclusion Criteria:

Ocular conditions-study eye

  • The absence of observable hyper-FAF at the margins of the GA in the study eye(only for lesions ≥ 0.25mm2)
  • Atrophic retinal disease of causality other than AMD including myopia-related maculopathy and monogenetic macular dystrophies including pattern dystrophy and adult-onset Stargardt disease in the study eye.
  • Presence or diagnosis of exudative AMD or CNV in the study eye.
  • Presence of retinal vein occlusion in the study eye.
  • Presence of diabetic retinopathy (a history of diabetes mellitus without retinopathy is not a criterion for exclusion) in either eye.
  • Presence of vitreous hemorrhage in the study eye.
  • History of retinal detachment in the study eye.
  • History of macular hole (stages 2 to 4) in the study eye.
  • Presence of an epiretinal membrane that causes distortion of the retinal contour in the study eye.
  • Presence of vitreomacular traction in the study eye.
  • At the Screening Visit, advanced glaucoma resulting in a cup to disc ratio of > 0.8 in the study eye.
  • History of glaucoma filtration surgery or uncontrolled glaucoma defined as IOP > 22 mmHg at baseline despite anti-glaucoma treatment with or without topical anti-hypertensive eye drops in the study eye OR currently using > 2 medications (note: combination medications count as 2 medications).
  • Presence of visually significant cataract OR presence of significant posterior capsular opacity in the setting of pseudophakia. Significant cataract is defined as > +2 nuclear sclerosis based upon the scale below or any Posterior Subcapsular Cataract in the study eye. The Sponsor, or its designee, will supply the trial sites with a copy of the standard photographs.
  • Presence of significant keratopathy or any other media or corneal opacity that would cause scattering of light or alter visual function, especially in LL conditions in the study eye.
  • Ocular incisional or laser surgery (including cataract surgery) in the study eye within 90 days before Day 1.
  • Yag laser capsulotomy in the study eye within 30 days before Day 1.
  • Aphakia in the study eye.
  • History of vitrectomy surgery, submacular surgery, or any vitreoretinal surgery in the study eye.
  • Prior treatment with Visudyne® (verteporfin) ocular photodynamic therapy, external-beam radiation therapy (for intraocular conditions), or transpupillary thermotherapy in the study eye.
  • History of subthreshold laser treatment or other forms of photobiomodulation for AMD in the study eye.
  • Intravitreal drug delivery in the past 60 days or 5-half-lives of the injected drug whichever is longer (e.g., intravitreal injection, anti angiogenic drugs, or device implantation) in the study eye.
  • Current use of medications known to be toxic to the lens, retina, or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine [Plaquenil®], tamoxifen, phenothiazines, ethambutol, digoxin, and aminoglycosides) from the Screening Visit through the completion of the trial.

Ocular conditions--either eye

  • History of herpetic infection in either eye.
  • Concurrent disease in either the study eye or fellow control eye that could require medical or surgical intervention during the study period.
  • Active uveitis and/or vitritis (grade trace or above) in either eye.
  • History of idiopathic or -associated uveitis in either eye.
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.

Systemic conditions.

  • Known to be or receiving systemic immunosuppression for ≥ 4 consecutive weeks prior to screening.
  • Any disease or medical condition that in the opinion of the Investigator would prevent the subject from successfully participating in the study or might confound study results.

General

  • Participation in other drug or device clinical studies within 30 days of enrollment and/or planning to participate in any other investigational drug or device clinical studies within 30 days of study completion.
  • History of allergy to fluorescein that is not amenable to treatment.
  • of ≤ 30 mL/min at the Screening Visit (using Modification of Diet in Renal Disease Study formula).
  • Inability to comply with study or follow-up procedures.
  • Inability to obtain color fundus photograph, FAF, and FA of sufficient quality to be analyzed and interpreted.
  • Active or any other cancer from which the subject has been cancer-free for \< 2 years.
  • History of allergic reaction to the investigational drug or any of its components.
  • Prior treatment with Elamipretide.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Elamipretide

    Once daily 40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.

    Combination Product: Subcutaneous elamipretide through the elamipretide delivery system

  • Placebo comparator
    Placebo

    Once daily subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.

    Combination Product: Subcutaneos placebo through the elamipretide delivery system

Interventions

  • Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.

    Also known as: elamipretide, MTP-131, Bendavia

  • Combination productSubcutaneos placebo through the elamipretide delivery system

    Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.

06

What researchers measure

Primary outcomes

  1. LL BCVA Score Change From Baseline

    Change in low luminance best corrected visual acuity (LL BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Time frame: Baseline and Weeks 4, 8, 12, 24, 36, 48

  2. GA Area Change From Baseline by OCT

    Geographic atrophy (GA) area: change from baseline as measured by optical coherence tomography (OCT) from Baseline to the end of treatment (EOT; Week 48)

    Time frame: Baseline and Weeks 12, 24, 36, 48

Secondary outcomes

  1. LL RA Change From Baseline

    Low-luminance ready acuity (LL RA) score change from baseline to the EOT (Week 48). Mean Critical Print Size with Low Luminance in Weeks 4, 12, 36, 48 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

    Time frame: Baseline and Weeks 4,12, 36, 48

  2. BCVA Change From Baseline

    Best-corrected visual acuity (BCVA) change from Baseline Change in best corrected visual acuity (BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Time frame: Baseline and Weeks 4, 8, 12, 24, 36, 48

  3. GA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline

    Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.

    Time frame: Baseline and Weeks 12, 24, 36, 48

Other outcomes

  1. Macular Percentage of Ellipsoid Zone (EZ) Total Attenuation From Baseline

    Change from Baseline in Macular Percentage of EZ Total Attenuation by OCT: Week 24 and Week 48 measures photoreceptor loss marked by EZ degradation. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

    Time frame: Baseline, Week 24 and Week 48

07

Results

Posted Oct 17, 2023

Participant flow

Participant flow — Overall Study
MilestoneElamipretidePlacebo
Started11759
Completed8351
Not completed348
Withdrew: Withdrawal by subject203
Withdrew: Adverse event104
Withdrew: Physician decision11
Withdrew: Protocol violation10
Withdrew: Lost to follow-up10
Withdrew: Covid-19 infection10

Outcome measures

PrimaryLL BCVA Score Change From Baseline

Change in low luminance best corrected visual acuity (LL BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

Time frame:
Baseline and Weeks 4, 8, 12, 24, 36, 48
Reported as:
Mean · Letters
LL BCVA Score Change From Baseline
LettersElamipretidePlacebo
Week 40.7 ± 6.11-0.6 ± 5.93
Week 81.1 ± 5.64-0.8 ± 7.71
Week 12-0.7 ± 9.35-0.9 ± 7.05
Week 24-0.9 ± 9.05-0.9 ± 6.80
Week 36-0.6 ± 12.21-3.2 ± 9.37
Week 48-2.8 ± 11.40-4.6 ± 11.89
PrimaryGA Area Change From Baseline by OCT

Geographic atrophy (GA) area: change from baseline as measured by optical coherence tomography (OCT) from Baseline to the end of treatment (EOT; Week 48)

Time frame:
Baseline and Weeks 12, 24, 36, 48
Reported as:
Mean · mm^2
GA Area Change From Baseline by OCT
mm^2ElamipretidePlacebo
Week 120.082 ± 0.08890.071 ± 0.0812
Week 240.166 ± 0.13910.166 ± 0.1426
Week 360.245 ± 0.16800.228 ± 0.1977
Week 480.328 ± 0.21660.281 ± 0.2407
SecondaryLL RA Change From Baseline

Low-luminance ready acuity (LL RA) score change from baseline to the EOT (Week 48). Mean Critical Print Size with Low Luminance in Weeks 4, 12, 36, 48 as measured by the Logarithm of the Minimum Angle of Resolution LogMAR chart. Scores range from -0.3 to 1.0, where higher number means worse acuity/worse outcome, a lower number means better acuity/better outcome.

Time frame:
Baseline and Weeks 4,12, 36, 48
Reported as:
Mean · units on a scale
LL RA Change From Baseline
units on a scaleElamipretidePlacebo
Week 4-0.005 ± 0.26780.029 ± 0.3169
Week 12-0.008 ± 0.34290.035 ± 0.3244
Week 360.002 ± 0.37760.073 ± 0.2761
Week 480.011 ± 0.40820.101 ± 0.3069
SecondaryBCVA Change From Baseline

Best-corrected visual acuity (BCVA) change from Baseline Change in best corrected visual acuity (BCVA) score from Baseline to the end of treatment (EOT; Week 48) assessment measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

Time frame:
Baseline and Weeks 4, 8, 12, 24, 36, 48
Reported as:
Mean · Letters
BCVA Change From Baseline
LettersElamipretidePlacebo
Week 40.3 ± 4.03-0.1 ± 4.51
Week 80.0 ± 4.880.9 ± 4.84
Week 12-0.2 ± 4.46-0.0 ± 6.14
Week 24-0.2 ± 5.09-0.2 ± 5.00
Week 36-1.5 ± 5.76-0.8 ± 6.13
Week 48-3.0 ± 6.90-2.6 ± 7.86
SecondaryGA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline

Change from Baseline in Mean Area of Geographic Atrophy (GA) by Fundus Autofluorescence (FAF) at Week 24. Fluorescein angiography (FA) was used to examine the circulation of the retina and choroid using fluorescein dye and a specialized camera to trace the dye. Fundus autofluorescence imaging of the retinal pigment epithelium and neurosensory retina was performed within 14 days of Day 0 and at every visit with the exception of Day 0 and Day 7. Atrophy is characterized by loss of the retinal pigment epithelium (RPE), overlying photoreceptors and underlying choriocapillaris. Greater area affected means a worse outcome than smaller area affected.

Time frame:
Baseline and Weeks 12, 24, 36, 48
Reported as:
Mean · mm^2
GA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline
mm^2ElamipretidePlacebo
Week 120.074 ± 0.06900.065 ± 0.0804
Week 240.161 ± 0.12180.138 ± 0.1338
Week 360.242 ± 0.16590.199 ± 0.1700
Week 480.318 ± 0.20600.277 ± 0.2176
Other pre-specifiedMacular Percentage of Ellipsoid Zone (EZ) Total Attenuation From Baseline

Change from Baseline in Macular Percentage of EZ Total Attenuation by OCT: Week 24 and Week 48 measures photoreceptor loss marked by EZ degradation. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percentage of EZ total attentuation
Macular Percentage of Ellipsoid Zone (EZ) Total Attenuation From Baseline
percentage of EZ total attentuationElamipretidePlacebo
Week 241.81 ± 3.8892.70 ± 3.291
Week 483.94 ± 4.0526.38 ± 6.616

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elamipretide2/117 (1.7%)18/117 (15.4%)83/117 (70.9%)
Placebo0/59 (0%)6/59 (10.2%)36/59 (61%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventElamipretidePlacebo
Corona virus infectionInfections and infestations2/1170/59
CholelithiasisHepatobiliary disorders2/1170/59
PneumoniaInfections and infestations2/1170/59
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1171/59
Lung carcinoma cell type unspecified stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1171/59
FallInjury, poisoning and procedural complications0/1171/59
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1171/59
Upper respiratory tract infectionInfections and infestations0/1171/59
Pancreatitis acuteGastrointestinal disorders0/1171/59
Glomerular filtration rate decreasedRenal and urinary disorders0/1171/59
Most frequent other events
Showing 10 of 27
Most frequent other events
EventElamipretidePlacebo
Injection Site PruritusGeneral disorders46/1170/59
Injection Site PainGeneral disorders33/1176/59
Injection Site ErythemaGeneral disorders22/1170/59
Injection Site BruisingGeneral disorders15/11711/59
Injection Site HaemorrhageGeneral disorders17/1174/59
Injection Site IndurationGeneral disorders16/1173/59
Urinary Tract InfectionInfections and infestations4/1177/59
Injection Site MassGeneral disorders13/1170/59
Injection Site SwellingGeneral disorders11/1170/59
Injection Site HypertrophyGeneral disorders10/1174/59

Baseline characteristics

All subjects that were randomized and received at least one dose of study drug and have baseline and at least one post-baseline value for LL BCVA or GA Area on OCT.

Age, Continuous
Age, Continuous(years)ElamipretidePlaceboTotal
Mean76.0 ± 8.4075.8 ± 8.8076.0 ± 8.51
Sex: Female, Male
Sex: Female, Male(Participants)ElamipretidePlaceboTotal
Female6836104
Male462268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ElamipretidePlaceboTotal
Hispanic or Latino224
Not Hispanic or Latino11153164
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ElamipretidePlaceboTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White11257169
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ElamipretidePlaceboTotal
United States11458172
Body Mass Index
Body Mass Index(kg/m^2)ElamipretidePlaceboTotal
Mean29.85 ± 6.47927.92 ± 5.38029.20 ± 6.181
GA Area (mm2) by OCT
GA Area (mm2) by OCT(mm^2)ElamipretidePlaceboTotal
Mean1.47 ± 0.7611.38 ± 0.6821.44 ± 0.734
LL BCVA Score
LL BCVA Score(Letters)ElamipretidePlaceboTotal
Mean53.4 ± 16.1758.8 ± 10.7055.2 ± 14.75

1 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • Associated Retina Consultants, Ltd.
    Peoria, Arizona 85381, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85014, United States
  • Arizona Retina & Vitreous Consultants
    Phoenix, Arizona 85021, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85053, United States
  • Global Retina Institute
    Scottsdale, Arizona 85254, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Retina Institute of California Medical Group
    Palm Desert, California 92260, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • California Retina Consultants
    Santa Maria, California 93454, United States
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • MedEye Associates
    Miami, Florida 33143, United States
  • Bascom Palmer Eye Institute
    Palm Beach Gardens, Florida 33418, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Cumberland valley retina consultants
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Specialty Eye Institute
    Jackson, Michigan 49202, United States
  • Retina Center of New Jersey LLC
    Bloomfield, New Jersey 07003, United States
  • New Jersey Retina
    Teaneck, New Jersey 07666, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Duke Eye center
    Durham, North Carolina 27705, United States
  • Sterling Research Group
    Cincinnati, Ohio 45202, United States
  • Oklahoma University Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Retina Northwest, P.C
    Portland, Oregon 97221, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Tennessee Retina
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Research Center, PLLC
    Austin, Texas 78705, United States
  • Ophthalmology Associates
    Fort Worth, Texas 76102, United States
  • Texas Retina Associates
    Fort Worth, Texas 76104, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • Retina Consultants of Houston
    Katy, Texas 77494, United States
  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
  • University of Virginia, Department of Ophthalmology
    Charlottesville, Virginia 22903, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Feb 2022, 34 months.

Results were first posted in Oct 2023, 1 year 7 months after primary completion.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 34 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 27, 2019
StartActual
Mar 27, 2019
Primary completionActual
Feb 22, 2022
CompletionActual
Apr 14, 2022
Results first posted
Oct 17, 2023
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03891875
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Mar 27, 2019
Primary completion
Feb 22, 2022
Completion
Apr 14, 2022
Results posted
Oct 17, 2023
Last update
Jul 12, 2024

Study contacts

Sathyanarayana
study director · Stealth BioTherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion